Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
19.4.2022 12:00:00 EEST | Business Wire | Press release
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Makes Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra Available on Real Device Cloud Ahead of Retail Launch5.8.2026 15:30:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, announced that the Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra are now available for testing on its Real Device Cloud. Both devices, unveiled at Samsung's Galaxy Unpacked event, run Android 17 with One UI 9 and are accessible for live testing and automation before retail units reach customers. The launch generation introduces a testing challenge new to the Galaxy Z Fold line. The Galaxy Z Fold8 unfolds into a portrait-oriented 7.6-inch display, while the Galaxy Z Fold8 Ultra, the first Ultra model in the Z series, unfolds into a landscape-oriented 8.0-inch display. Two devices that share a name, a chipset, and an operating system present layouts with opposite orientations, which means an interface validated on one can break on the other. "Samsung has introduced two foldables with opposite unfolded orientations in the same generation, and that kind of form-factor diversity is exact
Riskified and Marqeta Partner to Sharpen Card Issuer Authorization Decisions and Help Reduce False Declines5.8.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced a partnership with Marqeta (NASDAQ: MQ), the global modern card issuing platform, to give card issuers on Marqeta's platform access to Riskified's pre-authorization risk intelligence. The integration helps issuers make more accurate authorization decisions, approve more legitimate transactions, and reduce false declines across Marqeta's issuing portfolio. False declines remain one of ecommerce's most costly and least visible problems. According to 2023 research by PYMNTS Intelligence and Nuvei, false declines put an estimated $157 billion in U.S. ecommerce sales at risk, with $81 billion ultimately lost even after consumers attempted to complete their purchases through subsequent payment attempts. Because issuers typically make authorization decisions with limited visibility into the broader merchant-consumer relationship, they too often decline legitimate orders alongside genuinely fraudu
NTT DATA AI for Insurance Converts Complex Workflows into Governed, Repeatable AI-delivered Services5.8.2026 15:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced NTT DATA AI for Insurance, an AI-native agentic solution that converts complex core insurance workflows into governed, repeatable services. Built for highly regulated insurance environments, the Service-as-Software solution combines configurable AI agents, insurance-specific data models, workflow orchestration and enterprise-grade governance to maintain auditability, regulatory guardrails and human oversight. NTT DATA AI for Insurance helps carriers modernize underwriting, claims, customer service and other core insurance workflows while improving productivity across the enterprise. Powered by NTT DATA AIVista, the company's AI-native product platform, the solution combines a prebuilt insurance foundation with flexible configuration and targeted customization, enabling rapid deployment while adapting to each carrier's products, processes, operating model and regulatory requirements. The solution
‘Cheers to Beer’ Celebrates the Drink at the Heart of Life’s Meaningful Moments5.8.2026 15:00:00 EEST | Press release
Ahead of International Beer Day on August 7th, AB InBev, the world's leading brewer, launched “Cheers to Beer,” a new global campaign celebrating the timeless role beer plays in culture and communities around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805206698/en/ The campaign is anchored by a new film, created in partnership with Wieden+Kennedy, that celebrates the many moments of cheers that beer creates across geographies and generations. The film, which will be amplified globally, reinforces beer's role in life’s meaningful moments, big and small. “Beer is universal and woven into cultures and communities around the world,” said Michel Doukeris, CEO, AB InBev. “No matter who you are, what you do for a living, or where you live, when someone says, ‘Let’s grab a beer,’ you know it means something more. It’s an invitation to celebrate or to simply connect.” Beer’s enduring relevance is reinforced by a new
Tecnotree saavutti kaksinumeroisen tuloskasvun ja vauhditti toimituksia vuoden 2026 ensimmäisellä puoliskolla5.8.2026 14:04:00 EEST | Tiedote
Tecnotree, maailmanlaajuinen tekoälynatiivien digitaalisten liiketoiminnan tukijärjestelmien (BSS) ja televiestintäalan digitaalisten alustaratkaisujen toimittaja, julkisti vuoden 2026 ensimmäisen vuosipuoliskon taloudellisen tuloksensa. Yhtiö saavutti kasvua kaikissa keskeisissä taloudellisissa tunnusluvuissaan, paransi liikevoittomarginaaliaan 800 peruspisteellä ja eteni ennätyksellisen tilauskantansa toimittamisessa ripeästi. Pohjois-Amerikassa, Afrikassa ja Lähi-idässä toteutettiin yhteensä kahdeksan tuotantoonvientiä. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20260805483151/fi/ Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 2026 Ensimmäinen vuosipuolisko (tammi–kesäkuu 2026) Liikevaihto oli 36,8 miljoonaa euroa (34,2 miljoonaa euroa), mikä merkitsee 7,5 prosentin kasvua edellisvuodesta. Vertailukelpoisin valuuttakurssein liikevaihto oli 37,6 miljoonaa euroa, jossa kasvua ol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom